Retatrutide
10 mg
$ 3,200.00
Sale price
$ 3,200.00
Regular price
$ 3,350.00
Skip to product information
Retatrutide
$ 3,200.00
Sale price
$ 3,200.00
Regular price
$ 3,350.00
🏷 Descuento por cantidad
10%
5 – 9 unidades
20%
10 – 14 unidades
✦ MEJOR PRECIO
30%
15+ unidades
Agrega al carrito la cantidad deseada y el descuento se aplica automáticamente.
Research Reference — MVLabs.mx
Retatrutide (LY3437943)
The first triple hormone receptor agonist targeting GLP-1, GIP, and Glucagon receptors simultaneously — delivering bariatric-level weight loss in research settings.
⚠ For Research Purposes Only. All protocols, dosing information, and data on this page are provided exclusively for educational and scientific research reference. Retatrutide (LY3437943) is an investigational compound. It is not approved by the FDA or any regulatory authority for human use. All dosing ranges referenced are derived from published clinical research. MVLabs.mx products are strictly for in-vitro and research use only. Always consult a qualified medical professional.
What Is Retatrutide?
Overview, molecular class & development status
What Is Retatrutide?
Overview, molecular class & development status
Retatrutide (developmental code LY3437943) is a synthetic single-peptide molecule developed by Eli Lilly and Company. It is the world's first triple receptor agonist — simultaneously activating glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.[1]
Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist), retatrutide adds glucagon receptor activation, which drives direct thermogenesis and hepatic fat mobilization beyond what satiety-based mechanisms alone can achieve.[2]
Receptor Targets & Their Roles
Triple Receptor Mechanism
Adapted from: Jastreboff et al., NEJM 2023; Nature Cell Discovery 2024 [1,3]
Development Timeline
- 2021: Phase 1 first-in-human study initiated (NCT04881760)
- June 2023: Phase 2 results published in New England Journal of Medicine
- 2024–2026: Phase 3 TRIUMPH program (5 trials)
- 2025: TRIUMPH-1 topline: up to 30.3% weight loss at 104 weeks
- FDA Approval: Pending (NDA submission expected late 2026)
Clinical Evidence
Phase 2 & Phase 3 TRIUMPH trial data
Clinical Evidence
Phase 2 & Phase 3 TRIUMPH trial data
30.3%
Max weight loss
Phase 3 · 104 weeks
70.3 lb
Avg. lost (12 mg)
TRIUMPH-1 · 80 wks
2,339
Participants
TRIUMPH-1 trial
3×
Receptor targets
GLP-1 · GIP · Glucagon
Phase 2 — Weight Loss by Dose (48 Weeks)[1]
Mean % Body Weight Change at 48 Weeks — Phase 2 (Jastreboff et al., NEJM 2023)
Source: Jastreboff AM et al. N Engl J Med. 2023;389:514-526
vs. Competing Agents
| Drug | Class | Max Weight Loss | Duration |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | −15.2% | 68 weeks |
| Tirzepatide (Zepbound) | GLP-1/GIP | −22.5% | 72 weeks |
| Retatrutide | GLP-1/GIP/Glucagon | −30.3% | 104 weeks |
Research Dosing Protocol
⚠ Research use only — not medical advice
Research Dosing Protocol
⚠ Research use only — not medical advice
Research Reference Only. Protocol derived from Phase 2 and Phase 3 clinical trial data. Strictly for in-vitro or pre-clinical research.
Reconstitution — 10 mg Vial (SKU: RT10)
10 mg + 2 mL BAC Water = 5 mg/mL
1 unit (U-100) = 0.01 mL = 50 µg · Store at 2–8 °C · Use within 28 days
Escalation Schedule (Phase 2 Protocol)
| Phase | Weekly Dose | Units (U-100) | Volume | Notes |
|---|---|---|---|---|
| Weeks 1–2 | 0.5 mg | 10 U | 0.10 mL | Per tolerance |
| Weeks 3–4 | 1 mg | 20 U | 0.20 mL | Per tolerance |
| Weeks 5–8 | 2 mg | 40 U | 0.40 mL | Per tolerance |
| Weeks 9–12 | 4 mg | 80 U | 0.80 mL | Per tolerance |
| Week 13+ | 8 mg | 160 U (2 syringes) | 1.60 mL | Max — do not exceed |
🧮 MVLabs.mx Peptide CalculatorEnter your vial size and BAC water to auto-calculate units & volume for any dose
Open Calculator →
Safety Profile & Tolerability
Phase 2 adverse event data — research reference
Safety Profile & Tolerability
Phase 2 adverse event data — research reference
Adverse events in Phase 2 were predominantly gastrointestinal, dose-dependent, and mostly mild-to-moderate in severity — occurring primarily during dose escalation.
Most Common Adverse Events (8 mg group, Phase 2)
Key Safety Notes
- GI adverse events primarily occur during dose escalation — not at steady state
- No significant hypoglycemia in non-diabetic subjects
- Heart rate increase: +2–4 bpm at higher doses
- No serious pancreatitis events in Phase 2
- Discontinuation rates: 6–16% depending on dose
Reconstitution & Storage Guide
Step-by-step lab preparation reference
Reconstitution & Storage Guide
Step-by-step lab preparation reference
Standard Reconstitution
10 mg vial + 2 mL Bacteriostatic Water
= 5 mg/mL (5,000 µg/mL) · 1 U-100 unit = 50 µg · 1 mL = 5 mg
Step-by-Step Procedure
- Allow the lyophilized vial to reach room temperature (~15 min)
- Clean rubber stoppers with 70% isopropyl alcohol
- Draw 2.0 mL of bacteriostatic water into a clean 3 mL syringe
- Inject water slowly down the side — do not spray onto powder
- Gently swirl (no vortex/shake) until dissolved — clear and colorless
- Discard if cloudiness or particles visible
- Label with reconstitution date, store at 2–8 °C
Storage Conditions
| State | Temperature | Shelf Life | Notes |
|---|---|---|---|
| Lyophilized (powder) | −20 °C (freezer) | 12–24 months | Keep desiccated & dark |
| Lyophilized (powder) | 2–8 °C (fridge) | 3–6 months | Avoid freeze-thaw cycles |
| Reconstituted | 2–8 °C (fridge) | 28 days | Do not freeze |
🧮 Calculate Your DoseUse the MVLabs.mx Peptide Calculator to convert mg doses to syringe units instantly
Open Calculator →
Research Literature & Official Sources
Peer-reviewed studies, Lilly data, clinical trials
Research Literature & Official Sources
Peer-reviewed studies, Lilly data, clinical trials
- Jastreboff AM et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389:514-526. 🔗 NEJM
- Eli Lilly. TRIUMPH-1 Phase 3 Topline Results, 2025. 🔗 Lilly
- Zhang Y et al. "Structural insights into triple agonism at GLP-1R, GIPR and GCGR by retatrutide." Cell Discovery. 2024. 🔗 Nature
- PMC Review 2025. "Retatrutide — A Game Changer in Obesity Pharmacotherapy." 🔗 PMC
🧮 MVLabs.mx Peptide CalculatorCalculate exact units and volumes for Retatrutide and 50+ research peptides
Open Calculator →
Product Specifications
| Purity | ≥99% HPLC |
| Format | Lyophilized powder |
| Quantity | 10 mg per vial |
| SKU | RT10 |
| Storage | 2–8°C · Protect from light |
| Intended use | Research use only — not for human consumption |
References
- Jastreboff AM et al. N Engl J Med. 2023;389:514-526. DOI
- Finan B et al. Sci Transl Med. 2013. [Dual/triple agonist rationale]
- Zhang Y et al. Cell Discovery. 2024. Nature
© 2026 MVLabs.mx. For research and educational purposes only. Not intended for human consumption. Always consult a licensed healthcare professional. Peptide Calculator
You may also like
Seguridad garantizada
Este producto cumple con los más altos estándares de seguridad y calidad.
- Certificación de calidad internacional
- Materiales no tóxicos y seguros
- Probado en laboratorios certificados
- Garantía de satisfacción 100%